EMEND® (SUSPENSION)

Drug Information Related Patent

Hold Company

MERCK SHARP DOHME

Learn More

Dosage and Administration

FOR SUSPENSION;ORAL

Specification

125MG/KIT

Indication

EMEND® is indicated for patients 6 months and older for the prevention of: acute and delayed nausea and vomiting associated with initial and repeat courses of hyperemetogenic cancer chemotherapy (HEC) including high-dose cisplatin, and nausea and vomiting associated with MEC.

Use

Instructions for Use

API

APREPITANT

API Structure

We Supply

APREPITANT

Note:

USP/CP/JP
Facility GMP
USMF/ASMF/JPMF/DMF/CEP/CDE

null

Note:

null

Note:

null

Drug Patent

Patent No	Expiration Date
8258132	2027/9/26

API Patent

Patent No	Expiration Date
8258132	2027/9/26

Note: The patent information provided herein is derived solely from publicly available data in the FDA Orange Book (or other cited sources) and is presented for general informational purposes only. Actual patent status may vary based on jurisdictional rulings, regulatory extensions or other factors.

HOURS

Daily: 9.30 AM–6.00 PM
Sunday : 9.30 AM–1.00 PM
Holidays: Closed

INFORMATION

Tel:
E-mail:
Address:
WhatsAPP

Member of

CERTIFICATION